Related Experiment Video

Updated: Mar 18, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

5.5K

A place for precision medicine in bladder cancer: targeting the FGFRs

Erica di Martino1, Darren C Tomlinson2, Sarah V Williams1

  • 1Section of Molecular Oncology, Leeds Institute of Cancer & Pathology, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK.

Future Oncology (London, England)
|July 7, 2016
PubMed

Insights

Fibroblast growth factor receptors (FGFRs) are frequently altered in bladder tumors. Targeting these FGFR alterations shows promise for new bladder cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Bladder cancer exhibits diverse molecular profiles and clinical outcomes.
  • Muscle-invasive bladder cancer (MIBC) has a poor prognosis, necessitating novel systemic therapies.
  • Non-muscle-invasive bladder cancer (NMIBC) has a good prognosis but high recurrence rates, demanding lifelong monitoring.

Purpose of the Study:

  • To review the molecular alterations of Fibroblast Growth Factor Receptors (FGFRs) in bladder tumors.
  • To summarize preclinical evidence supporting FGFRs as therapeutic targets.
  • To discuss available FGFR-targeted agents and early clinical trial results in bladder cancer.

Main Methods:

  • Literature review of molecular alterations in bladder tumors.
  • Analysis of preclinical studies on FGFR-targeted therapies.
  • Summary of clinical trial data for FGFR inhibitors in bladder cancer.

Main Results:

  • Frequent alterations in FGFRs, including FGFR3 mutations and dysregulated FGFR1/FGFR3 expression, are observed in bladder tumors.
  • Preclinical studies validate FGFRs as actionable therapeutic targets.
  • Early clinical trials show potential for FGFR-targeted agents in bladder cancer treatment.

Conclusions:

  • FGFR alterations represent a significant molecular feature in bladder cancer.
  • Targeting FGFRs offers a promising therapeutic strategy for bladder cancer patients.
  • Further clinical investigation of FGFR-targeted therapies is warranted.
Keywords:
FGFR1FGFR3FGFRsbladdercancertargeted therapyurothelial

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.2K
Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine06:14

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine

Published on: September 19, 2025

1.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K